Otsuka Pharmaceutical to buy biotechnology firm Visterra for $430m
Visterra is engaged in the development of advanced antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Otsuka Pharmaceutical representative director and president